HIV / AIDS

International interdisciplinary collaboration will bring us that much closer to a cure for HIV.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

NIAID Vaccine Research Center scientists alters broadly neutralizing HIV antibody to make it last longer in the blood.

Infectious disease physicians often have to fight to garner the attention of policymakers.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

FDA recommends that health care providers practice caution before prescribing clarithromycin to patients with heart disease due to potentially fatal long-term risks.

PrEP does not have to be taken daily to be effective, but consistency and a strong support system are key.

A recent study finds a potential link between cannabis use and possible beneficial reduction in systemic inflammation and immune activation in ART-treated HIV patients.

Mylan NV's new drug application for its combo regimen of dolutegravir, emtricitabine, and tenofovir alafenamide, received tentative approval from the US Food and Drug Administration under the President's Emergency Plan for AIDS Relief (PEPFAR).

A recent CDC report finds those between 15 and 44 years of age are significantly more likely to have never been tested for HIV.

Advances in antiretroviral therapies increase opportunities for patients with HIV to have more successful treatment outcomes.

ViiV Healthcare has launched a phase 3 study to assess if adults with HIV-1 who have achieved viral suppression on a 3-drug regimen can maintain suppression when switched to a 2-drug regimen.

An international research team finds that targeting the social and risk networks of patients recently diagnosed with HIV is leading them to more patients unknowingly infected with the virus.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

The FDA approves Symfi Lo Tablets for the treatment of HIV-1 in adult and pediatric patients who weigh at least 35 kg.

Ideally, every individual with HIV would be able to receive ART in a timely fashion, but in resource-limited communities, it’s crucial to prioritize those who will most benefit.

Gilead Sciences, Inc.'s Biktarvy has been approved by the FDA for the treatment of those with HIV-1.

Contagion® celebrates its second year this month amid celebrations of bringing in its highest readership traffic to-date.

An ongoing study aims to confirm that newer ART regimens are as safe for pregnant women living with HIV as they are for their non-pregnant counterparts.

A multinational team of investigators has revealed a link between conflict-induced displacement of people and the spread of HIV within Ukraine.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Aetna has agreed to a $17 million settlement of a lawsuit centering around the HIV privacy violation that affected approximately 12,000 of the insurer’s customers in 2017.

The test combines the convenience of the saliva test with the reliability of the blood test.

Three medical centers in the United States have now been approved to perform kidney transplants from living HIV-positive donors to HIV-positive recipients. We break down the risks and benefits.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

University of Western Ontario investigators have found that the genetic diversity of HIV-1 during early infection is greater in the vaginal tract than in the bloodstream.

Teva Pharmaceuticals announces an exclusive launch of a generic version of atazanavir capsules for the treatment of HIV.

In case you missed them, we've compiled the top 5 articles from this past week.

A common birth control shot has been linked with increased risk of HIV infection while NIAID investigators have found that putting ART on pause during a clinical trial might not be as detrimental as first thought.

Investigators from the Massachusetts Institute of Technology, Brigham and Women's Hospital, and Lyndra, have developed a drug capsule that could drastically pare down ART to an easier-to-adhere-to weekly regimen.